Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer
/in Hyperthermia, International Publications, Ovarian Cancer /von 2004-04-01 / Int. J. Clin. Oncol. 2004 Apr;9(2):85-91Immunological treatment of ovarian cancer
/in International Publications, Ovarian Cancer /von 2004-02-01 / Curr. Opin. Obstet. Gynecol. 2004 Feb;16(1):87-92Dendritic cell-based vaccines in breast and gynaecologic cancer
/in Breast Cancer, Cervical Cancer, Dendritic Cells, International Publications, Ovarian Cancer /von 2003-09-01 / Anticancer Res. 2003 Sep-Oct;23(5b):4293-303TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients
/in International Publications, Ovarian Cancer /von 2003-04-01 / Clin. Cancer Res. 2003 Apr;9(4):1517-27Dendritic cells in vaccination therapies of malignant diseases
/in International Publications, Ovarian Cancer /von 2002-10-01 / Transfus. Apher. Sci. 2002 Oct;27(2):183-6Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer
/in International Publications, Ovarian Cancer /von 2002-04-01 / Minerva Ginecol 2002 Apr;54(2):133-44Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer
/in International Publications, Ovarian Cancer /von 2002-02-01 / Expert Rev Anticancer Ther 2002 Feb;2(1):97-105Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial
/in Dendritic Cells, Endometrial Cancer, International Publications, Ovarian Cancer /von 2002-01-10 / Cancer Immunol. Immunother. 2002 Mar;51(1):45-52Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer
/in Dendritic Cells, Endometrial Cancer, International Publications, Ovarian Cancer /von 2002-01-07 / Br. J. Cancer 2002 Jan;86(1):151-7IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de